AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01924104 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: NaCl
Description: Equivalent volume of NaCl 0.9%, subcutaneously
Study NCT02007655 — intervention group
Intervention type: DRUG
Intervention: Eliquis
Study NCT00815477 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-based lifestyle counseling messages
Description: 10 email messages based on readiness-to-change over a 4 month period
Study NCT00815477 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Generic Information
Description: Waitlist control plus educational material on lifestyle behavior and hyptertension
Study NCT01441856 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open or Laparoscopic left hemihepatectomy
Description: Patients in this arm will undergo a left hemihepatectomy within an Enhanced Recovery After Surgery Program.
Study NCT01441856 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open or Laparoscopic right hemihepatectomy
Description: Patients in this arm will undergo a right hemihepatectomy within an Enhanced Recovery After Surgery Program.
Study NCT00662428 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Symptom based discharge management
Description: Depressive symptoms of patients are weekly assessed by Beck Depression Inventory (BDI II). Patients are discharged when BDI-score is under 20 points. Patients are treated in the same hospital for two more weeks as outpatients before being referred to outpatient care (general practitioner or specialist).
Study NCT00662428 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Treatment as usual is the usual stationary depression treatment which consists of a combination of several psychopharmacological and psychotherapeutical treatments. Duration of treatment is varying widely.
Study NCT04404829 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual Therapy
Description: The first level of IMT was treated in this study: the objective is to harmonize the cranio-sacral and sacro-pelvic systems, as this is fundamental for maintaining good posture. The first therapeutic maneuvers should be focused on releasing of the sacrum and the pelvis. The first is considered a key area for the correct transmission of forces and loads from the lower limbs to the upper limbs and vice versa and shares the role of rigid elements for this purpose (bones) and tensile elements (muscles, ligaments, fascia) in the whole body. In this level. Compensatory injuries that the body has started after a primary injury are treated on this level, through the Fluidic Chains. The diagnosis of this level is performed by cranial somotopias. Practically all the treatment is carried out on the sacrum. The first step are the fuses, which are vibration zones which act as a protection system for the body. These points sometimes stop working, which interrupts the correct movement of the PRM.
Study NCT00631163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferasirox (ICL670)
Description: The recommended initial daily dose of Deferasirox is 20 mg/kg body weight.
Study NCT01300156 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin-based chemotherapy (ESHAOx)
Description: * Etoposide 40 mg/m2, D1-4~* Methylprednisolone 500mg, D1-5~* Cytarabine 2 g/m2, D5~* Oxaliplatin 130 mg/m2, D1
Study NCT01080859 — intervention group
Intervention type: DEVICE
Intervention: OCT
Description: Optical coherence tomography
Study NCT02208050 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Fampridine
Study NCT02208050 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Study NCT00421109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bilastine
Description: Encapsulated 20 mg Tablet. Once daily for 28 days
Study NCT00421109 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levocetirizine
Description: Encapsulated 5 mg tablet. Once daily for 28 days
Study NCT00421109 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Encapsulated tablet. Once daily for 28 days
Study NCT02945111 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Real-time view
Study NCT02945111 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: No visual support
Study NCT00579332 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: brassica intervention
Description: diet and phyto-chemical intervention
Study NCT00579332 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: brassica intervention
Description: diet and phyto-chemical intervention
Study NCT02290379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNX-201 35 mg
Description: Drug: TNX-201 35 mg
Study NCT02290379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNX-201 70 mg
Description: Drug: TNX-201 70 mg
Study NCT02290379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNX-201 140 mg
Description: Drug: TNX-201 140 mg
Study NCT02290379 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Racemic isometheptene 70 mg
Description: Active Comparator: Racemic isometheptene 70 mg
Study NCT02290379 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Drug: Placebo
Study NCT03372642 — intervention group
Intervention type: DEVICE
Intervention: Subtalar endorthesis
Description: Subtalar arthroereisis with endorthesis for pediatric flexible flat foot
Study NCT01685385 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patients who will receive the BNP test
Description: Patients in Diagnostic Intervention Group A will receive the point-of-care BNP test, in addition to all other diagnostics they receive in addition
Study NCT03871829 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carfilzomib 20 mg/m^2
Description: Carfilzomib 20 mg/m\^2 will be administered intravenously (IV).
Study NCT03871829 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib 20 mg/m^2
Description: Carfilzomib 20 mg/m\^2 will be administered intravenously (IV).
Study NCT03871829 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carfilzomib 70 mg/m^2
Description: Carfilzomib 70 mg/m\^2 will be administered IV.
Study NCT03871829 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib 70 mg/m^2
Description: Carfilzomib 70 mg/m\^2 will be administered IV.
Study NCT03871829 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone 40 mg
Description: Dexamethasone 40 mg will be administered as IV infusion or orally.
Study NCT03871829 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone 40 mg
Description: Dexamethasone 40 mg will be administered as IV infusion or orally.
Study NCT03871829 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dara-SC 1800 mg
Description: Dara-SC 1800 mg will be administered by SC injection.
Study NCT03871829 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone 20 mg
Description: Dexamethasone 20 mg will be administered as IV infusion or orally.
Study NCT03871829 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone 20 mg
Description: Dexamethasone 20 mg will be administered as IV infusion or orally.
Study NCT00528073 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin-EIR
Description: Comparison of 800 mg, 1600 mg and 2400 mg Rifaximin-EIR versus placebo in the treatment of active moderate Crohn's disease
Study NCT00528073 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rifaximin-EIR
Description: Comparison of 800 mg, 1600 mg and 2400 mg Rifaximin-EIR versus placebo in the treatment of active moderate Crohn's disease
Study NCT00715520 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation (TMS)
Description: Each TMS training session will begin with a baseline measurement lasting about 30 minutes in which brief magnetic pulses will be generated by the single-pulse and paired pulse TMS stimulator and the responses are recorded with surface EMG electrodes. Participants will be instructed to move their wrist for up to ½ hour. After these measures, rTMS will be applied to the scalp during training. Stimulation will occur at a low rate of different frequencies and different times with respect to the training movement depending on the experimental condition. In the last phase of the session post-training measurements will be done using single TMS pulses. TMS pulses and intensity with be given in random order.
Study NCT00715520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbidopa-Levodopa
Description: Participants will receive one oral dose of carbidopa-levodopa 25mg one hour prior to measuring wrist extension movements.~The order in which Carbidopa-Levodopa is given will be randomized per participant.
Study NCT00715520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Description: Participants will receive one oral dose of methylphenidate 40mg 2 hours prior to measuring wrist extension movements.~The order in which Methylphenidate is given will be randomized per participant.
Study NCT00715520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amphetamine Sulfate
Description: Participants will receive one oral dose of amphetamine sulfate 10mg 2 hours prior to measuring wrist extension movements.~The order in which Amphetamine Sulfate is given will be randomized per participant.
Study NCT00715520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive one oral tablet of placebo 2 hours prior to measuring wrist extension movements.~The order in which Placebo is given will be randomized per participant.
Study NCT00715520 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sham Transcranial Magnetic Stimulation (TMS)
Description: Sham TMS pulses will be randomly administered during TMS sessions.
Study NCT00715520 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation (TMS) Training
Description: TMS surface electromyographic activity will be recorded with surface electrodes mounted on the skin overlaying a forearm muscle. Single pulses of TMS at increasing intensity will be delivered to measure motor cortex excitability. Peak acceleration and TMS evoked responses in the muscle will be measured prior to the training, after completion of the training and again one hour after completion of the training.
Study NCT03705845 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo softgel
Description: Each placebo softgel of 430 mg olive oil will contain no TT or tocopherols at detectable levels.
Study NCT03705845 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DeltaGold® Tocotrienol 70%
Description: DeltaGold® Tocotrienol 70% contains 430 mg tocotrienol (90% δ-tocotrienol + 10% γ-tocotrienol) with a 70% purity, representing 300 mg tocotrienol.
Study NCT02546596 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electro-hyperthermia
Description: Addition of electro-hyperthermia to radiation
Study NCT05376072 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electromyographic Biofeedback
Description: The players performed 10 work sessions with EMG-BF. Each session was divided into three phases: (a) three trials without receiving feedback, (b) between six and ten trials with feedback of electromyographic activity, (c) three trials without feedback. In each trial, isometric contractions of the vastus lateralis were performed.~During maximum effort isometric contraction, the software associated with the ProComp Infiniti biofeedback unit collects the amplitude, the mean and maximum electromyographic signal, and also the contraction and tightening times. The contrac-tion time comprises the interval between the start of the contraction and achievement of the desired muscle tension. The tightening time is the period in which the tension voluntarily reached is maintained. For this study, the maximum and mean elec-tromyographic activity values were considered, calculated during the muscle tension time and maintained during each trial.
Study NCT01378715 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin
Description: Patients with coronary artery disease referred for coronary angiography and subsequently PCI will be enrolled and randomized to pre-treatment with rosuvastatin (20mg 12 hours prior + 20mg immediately prior PCI).
Study NCT02411617 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Drain
Description: Post modified radical mastectomy with either one or two drains Intervention is use of single or double drain
Study NCT02185898 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Leading U.S. non-menthol cigarette
Description: Tobacco-burning non-menthol cigarette
Study NCT02185898 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Leading U.S. menthol cigarette
Description: Tobacco-burning menthol cigarette
Study NCT02185898 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic cigarette #1
Description: Electronic cigarette
Study NCT02185898 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic cigarette #2
Description: Electronic cigarette
Study NCT02185898 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic cigarette #3
Description: Electronic cigarette
Study NCT02185898 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: U.S. Market-sample electronic cigarettes
Description: Marketed electronic cigarettes
Study NCT04231162 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Active product
Description: Bifidobacterium lactis HN019 (probiotic powder). One capsule to consume orally with still water (not sparkling) at room temperature once a day at least 15 minutes before breakfast time.
Study NCT04231162 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control product
Description: Placebo. One capsule to consume orally with still water (not sparkling) at room temperature once a day at least 15 minutes before breakfast time.
Study NCT00969969 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Arthrodesis
Description: arthrodesis using screws and/or a plate
Study NCT00969969 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cartiva
Description: Cartiva Synthetic Cartilage Implant
Study NCT01733589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human endostatin
Description: Recombinant human endostatin(7.5mg/m2/24h) Continued Pumping Into Vein through 5 days at week 1, 3, 5, and 7,combined with concurrent chemo-radiotherapy.
Study NCT01733589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide (50mg/m2) IV (in the vein) on day 1 to day 5 of a 28-day cycle for 2 cycles
Study NCT01733589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatinum (50mg/m2) IV (in the vein) on day 1 and day 8 of a 28-day cycle for 2 cycles
Study NCT01733589 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Study NCT01733589 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CT perfusion imaging
Study NCT01010204 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: Patients will be randomly assigned to receive either varenicline or placebo for 12 weeks. Patients assigned to varenicline will receive 0.5mg by the oral route once a day for 3 days, followed by 0.5mg twice a day for 4 days. After the first week the dose will be increased to 1mg twice daily for the remainder of the active treatment period of the study, i.e. 11 weeks. Patients assigned to placebo will receive identical looking capsules in a dosage schedule similar to varenicline. Patients will be instructed to take study medication after meals with a glass of water.
Study NCT02530697 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meglumine antimoniate
Description: 20mgSb+5/kg/day meglumine antimoniate intravenous for 28 days.
Study NCT02530697 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meglumine antimoniate
Description: 20mgSb+5/kg/day meglumine antimoniate intravenous for 28 days.
Study NCT02530697 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Miltefosine
Description: Miltefosine 2,5mg/kg/day up to 50mg 2x/daily.
Study NCT02530697 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pentoxifylline
Description: Pentoxifylline 20mg/kg/day up to 400mg 3x/daily for 28 days.
Study NCT02530697 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Description: Pentoxifylline 20mg/kg/day up to 400mg 3x/daily for 28 days.
Study NCT01733992 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: R348 Ophthalmic Solution, 0.2%
Description: R348 Ophthalmic Solution, 0.2% single and multiple ascending dose
Study NCT01733992 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: R348 Ophthalmic Solution, 0.5%
Description: R348 Ophthalmic Solution, 0.5%, single and multiple ascending dose
Study NCT01733992 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: R348 Ophthalmic Solution, 1.0%
Description: R348 Ophthalmic Solution, 1.0%, single and multiple ascending dose
Study NCT01733992 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, single and multiple ascending dose
Study NCT01733992 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo, single and multiple ascending dose
Study NCT02128334 — intervention group
Intervention type: DRUG
Intervention: Eligard 45 mg Exposure
Description: Subcutaneous injections
Study NCT03642600 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: dietary advice plus myo-inositol and folic acid
Description: dietary advice and lifestyle interventions and myo-inositol
Study NCT03642600 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dietary advice plus Liraglutide Pen Injector
Description: dietary advice and lifestyle interventions and liraglutide pen injector
Study NCT03688802 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OC-01 (varenicline) nasal spray
Description: OC-01 (varenicline) nasal spray
Study NCT03688802 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (vehicle control) nasal spray
Description: Placebo
Study NCT04059341 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low Intensity Extracorporeal Shockwave Therapy (LI-ESWT)
Description: Five sessions of penile Low Intensity Extracorporeal Shockwave Therapy initiated three weeks after radical prostatectomy.
Study NCT04059341 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Low Intensity Extracorporeal Shockwave Therapy (LI-ESWT)
Description: Five sessions of penile Low Intensity Extracorporeal Shockwave Therapy initiated three weeks after radical prostatectomy.
Study NCT03208413 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: Thalidomide with a dosage of 25 mg at bedtime daily one week (days 1-7), then 50 mg at bedtime daily for one week (days 8-14), then 75 mg at bedtime daily for one week (days 15-21), then 100 mg at bedtime daily for 12 weeks (days 22-105), in the absence of unacceptable toxicity or severe deterioration.
Study NCT02278705 — intervention group
Intervention type: OTHER
Intervention: Attention to BMI
Description: Evidence (using electronic health record data) denoting provider attention to about high BMI.
Study NCT02278705 — intervention group
Intervention type: OTHER
Intervention: Attention to high-BMI-related Medical Risk
Description: Evidence (using electronic health record data) denoting provider attention to high-BMI-related medical risk, including from high blood pressure/hypertension, cholesterol/dyslipidemia, blood sugar/diabetes, liver enzymes/fatty liver, and low vitamin D/vitamin-D deficiency.
Study NCT02278705 — intervention group
Intervention type: OTHER
Intervention: No attention to high BMI or high-BMI-related medical risk
Description: Lack of evidence (using electronic health record data) denoting provider attention to high BMI or high-BMI-related medical risk.
Study NCT04137341 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG1972 - A
Description: Film-coated tablet, formulation A
Study NCT04137341 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG1972 - B
Description: Film-coated tablet, formulation B
Study NCT04137341 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG1972 - C
Description: Film-coated tablet, formulation C
Study NCT02940873 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HARPdoc courses
Description: A six week group education package including hypoglycaemia-focussed cognitive behavioural therapy
Study NCT02940873 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: BGAT courses
Description: A structured psycho-education programme focussing on better prediction and recognition of high and low blood glucose values
Study NCT02587754 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Acupuncture
Description: 10 sessions of acupuncture, twice a week over 5 weeks.
Study NCT02587754 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Description: 10 sessions of acupuncture, twice a week over 5 weeks.
Study NCT01381380 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Manual therapy
Description: Manual therapy, once a week for 8 weeks